Keeping you updated on the latest Medicare and Part D news

Orphan Drug Spending Concerns May Be Unwarranted

1 Comment

The 1983 Orphan Drug Act provides drug manufacturers a period of exclusivity and financial incentives to produce drugs to treat diseases that affect fewer than 200,000 people. Many have speculated that an increase of FDA approved orphan drugs in recent years could be partially responsible for the rapidly increasing prescription drug spending. A recently published study conducted by IMS Health, a health care analytics firm, and drugmaker Celgene Corp. however found that orphan drug spending increased 4.8% from 2007 to 2013, compared with an 8.9% increase of total pharmaceutical spending.

Celgene has benefited handsomely from the Orphan Drug Act though and is predicted to be the number 1 orphan drug manufacturer in the world by sales in 2020. Because some orphan drugs are used to treat multiple conditions, some of which could be common, there may be incentives for drug companies to apply for orphan status even though the drug has the potential to be used by many more than 200,000 people.




One thought on “Orphan Drug Spending Concerns May Be Unwarranted

  1. Pingback: Orphan Drugs Used to Treat Common Conditions May Lead to Higher Prices | AcuPartD

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s